↵bAnalyses stratified by weight loss percentage and using all available data (participants randomized to intervention arms with missing 12-month weight were classified as having no change/gained).

↵cP value obtained from GEE model comparing the difference in change of the biomarkers from baseline to 12-month in intervention group versus control within strata of percent weight loss, adjusted for age, baseline BMI (<30 kg/m2, ≥30 kg/m2), race/ethnicity (White, Black, and others), NSAID use, and statins use.

↵dP value obtained from GEE model testing the linear trend in the change of the biomarkers from baseline to 12-month from control through all levels of percent weight loss, adjusted for age, baseline BMI (<30 kg/m2, ≥30 kg/m2), race/ethnicity (White, Black, and others), NSAID use, and statins use.

Table 4.

Change in levels of analytes by tertiles of percent change in VO2max levels (mL/kg/min), compared with controls

↵bP value obtained from GEE model comparing the difference in change of the biomarkers from baseline to 12 months in intervention group versus control within tertiles of percent change in VO2max.

↵cP-value obtained from GEE model testing the linear trend in the change of the biomarkers from baseline to 12 months from control through all tertiles of percent change in VO2max. All models adjusted for age, baseline BMI (<30 kg/m2, ≥30 kg/m2), race/ethnicity (White, Black, and others), NSAID use, and statins use.